Your browser doesn't support javascript.
loading
Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes.
Leelarathna, Lalantha; Evans, Mark L; Neupane, Sankalpa; Rayman, Gerry; Lumley, Sarah; Cranston, Iain; Narendran, Parth; Barnard-Kelly, Katharine; Sutton, Christopher J; Elliott, Rachel A; Taxiarchi, Vicky P; Gkountouras, Georgios; Burns, Matthew; Mubita, Womba; Kanumilli, Naresh; Camm, Maisie; Thabit, Hood; Wilmot, Emma G.
Afiliação
  • Leelarathna L; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Evans ML; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Neupane S; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Rayman G; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Lumley S; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Cranston I; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Narendran P; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Barnard-Kelly K; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Sutton CJ; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Elliott RA; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Taxiarchi VP; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Gkountouras G; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Burns M; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Mubita W; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Kanumilli N; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Camm M; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Thabit H; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
  • Wilmot EG; From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and
N Engl J Med ; 387(16): 1477-1487, 2022 10 20.
Article em En | MEDLINE | ID: mdl-36198143
ABSTRACT

BACKGROUND:

In persons with type 1 diabetes and high glycated hemoglobin levels, the benefits of intermittently scanned continuous glucose monitoring with optional alarms for high and low blood glucose levels are uncertain.

METHODS:

In a parallel-group, multicenter, randomized, controlled trial involving participants with type 1 diabetes and glycated hemoglobin levels between 7.5% and 11.0%, we investigated the efficacy of intermittently scanned continuous glucose monitoring as compared with participant monitoring of blood glucose levels with fingerstick testing. The primary outcome was the glycated hemoglobin level at 24 weeks, analyzed according to the intention-to-treat principle. Key secondary outcomes included sensor data, participant-reported outcome measures, and safety.

RESULTS:

A total of 156 participants were randomly assigned, in a 11 ratio, to undergo intermittently scanned continuous glucose monitoring (the intervention group, 78 participants) or to monitor their own blood glucose levels with fingerstick testing (the usual-care group, 78 participants). At baseline, the mean (±SD) age of the participants was 44±15 years, and the mean duration of diabetes was 21±13 years; 44% of the participants were women. The mean baseline glycated hemoglobin level was 8.7±0.9% in the intervention group and 8.5±0.8% in the usual-care group; these levels decreased to 7.9±0.8% and 8.3±0.9%, respectively, at 24 weeks (adjusted mean between-group difference, -0.5 percentage points; 95% confidence interval [CI], -0.7 to -0.3; P<0.001). The time per day that the glucose level was in the target range was 9.0 percentage points (95% CI, 4.7 to 13.3) higher or 130 minutes (95% CI, 68 to 192) longer in the intervention group than in the usual-care group, and the time spent in a hypoglycemic state (blood glucose level, <70 mg per deciliter [<3.9 mmol per liter]) was 3.0 percentage points (95% CI, 1.4 to 4.5) lower or 43 minutes (95% CI, 20 to 65) shorter in the intervention group. Two participants in the usual-care group had an episode of severe hypoglycemia, and 1 participant in the intervention group had a skin reaction to the sensor.

CONCLUSIONS:

Among participants with type 1 diabetes and high glycated hemoglobin levels, the use of intermittently scanned continuous glucose monitoring with optional alarms for high and low blood glucose levels resulted in significantly lower glycated hemoglobin levels than levels monitored by fingerstick testing. (Funded by Diabetes UK and others; FLASH-UK ClinicalTrials.gov number, NCT03815006.).
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemoglobinas Glicadas / Automonitorização da Glicemia / Diabetes Mellitus Tipo 1 Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemoglobinas Glicadas / Automonitorização da Glicemia / Diabetes Mellitus Tipo 1 Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article